Feature Article

Stress and Psoriasis: What Is the Connection?


As patients commonly cite stress as a precipitating or exacerbating factor for psoriasis, relieving psychological distress should be part of the treatment strategy.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News


Psoriasis Remission After HCV Treatment: Case Report

January 19, 2018

The patient's skin lesions started to resolve gradually soon after initiation of ledipasvir-sofosbuvir therapy.


Pediatric Psoriasis Associated With Increased Risk for Comorbidity Development

By January 16, 2018

The results suggest that dermatologists and pediatricians should be more proactive in screening for comorbidities in this population.


Psoriasis Treatment With Biologic, Systemic Therapies Has No Effect on Herpes Zoster Risk

By January 10, 2018

There was little difference in risk of herpes zoster among patients who were or weren't taking biologic or systemic therapies.


Long-Term, Real-Life Outcomes of Secukinumab for Plaque Psoriasis Fall Short

By January 03, 2018

Patients are more likely to discontinue use of secukinumab in real-life compared with patients evaluated in randomized controlled trials.


Ixekizumab Superior for Moderate to Severe Plaque Psoriasis

By January 03, 2018

With head-to-head randomized studies comparing the 2 biologic agents for the treatment of psoriasis not available, evidence obtained through indirect comparisons was used.


Infection Rates in Patients With Psoriasis Treated With Ixekizumab

By December 19, 2017

Infection rates were similar in patients treated with ixekizumab and placebo.


Combination Therapy Accelerates Clinical Response in Plaque Psoriasis

By December 18, 2017

The addition of phototherapy helps promote a quicker response to treatment in patients with plaque psoriasis.


Psoriasis, Psoriatic Arthritis Associated With Increased Risk for Liver Disease

By December 15, 2017

The greater the body surface area affected by psoriasis, the greater the risk for liver disease and cirrhosis.


FDA Approves Topical Treatment for Plaque Psoriasis

By December 12, 2017

The FDA has approved Impoyz Cream, a highly potent topical steroid, for the treatment of moderate-to-severe plaque psoriasis.


Comparing Biologics for the Long-Term Treatment of Plaque Psoriasis

By December 11, 2017

This Danish cohort study provides real-life data on newer biologic agents, such as secukinumab, and compares the data to biosimilar agents.

Sign up for Newsletters